Taking it to the next level

One of our goals as an organization is to bridge the drug development gap and bring promising therapies to the next level of funding. A terrific example of this goal in action is Celgene’s recent purchase of LLS partner, Avila Theraputics.

LLS recognized the potential in Avila’s protein silencing therapy to treat B-cell cancers back in 2010 and helped bring a molecule called AVL-292 to Phase 1 clinical trials. LLS’s early investment allowed Avila to quickly advance the molecule. Now with the drug in Celgene’s very capable hands, there is high confidence that its full potential will be unlocked.

All too often research advances are inhibited by a lack of funding. In the case of Avila, LLS was able to financially bridge the gap and set AVL-292 on the track to success. Now the brilliant minds at Celgene can work their magic and help this train reach its destination and deliver a new therapy to patients.


About Megan Kilkenny

LLS Sr. Director, Marketing Communication Team In Training Alum Three-time Nike Women's Half Marathon finisher
This entry was posted in Blood Cancer Research, LLS Partners and tagged , , . Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s